Methylprednisolone and other confounders to spinal cord injury clinical trials

Nature Clinical Practice Neurology

Volumn 2, Issue 8, 2006, Pages 402-403

  Sipski, Marca L ^a   Pearse, Damien D ^b  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BA 210; CETHRIN; CYCLOSPORIN A; ERYTHROPOIETIN; FAS ANTIBODY; GANGLIOSIDE GM1; GROWTH FACTOR; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; INTERLEUKIN 1BETA ANTIBODY; METHYLPREDNISOLONE; MINOCYCLINE; MONOCLONAL ANTIBODY; NEUROPROTECTIVE AGENT; NEUROTROPHIN; PROTEIN NOGO; TACROLIMUS; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; CLINICAL TRIAL; CORTICOSTEROID INDUCED MYOPATHY; DRUG APPROVAL; DRUG MEGADOSE; DRUG TARGETING; DRUG USE; EUROPE; FOOD AND DRUG ADMINISTRATION; GENE SILENCING; HUMAN; IMMUNOMODULATION; NEUROPROTECTION; PRIORITY JOURNAL; REVIEW; SPINAL CORD INJURY; UNITED STATES;

CLINICAL TRIALS; HUMANS; METHYLPREDNISOLONE; NEUROPROTECTIVE AGENTS; SPINAL CORD INJURIES;

EID: 33746573319     PISSN: 1745834X     EISSN: 17458358     Source Type: Journal    
DOI: 10.1038/ncpneuro0221     Document Type: Review

References (11)

1. Bracken MB et al. (1990) A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury: Results of the second National Acute Spinal Cord Injury Study. N Engl J Med 322: 1405-1411
2. Fehlings MG (2001) Recommendations regarding the use of methylprednisolone in acute spinal cord injury: Making sense out of the controversy. Spine 26 (Suppl): S56-S57
3. Qian T et al. (2005) High-dose methylprednisolone may cause myopathy in acute spinal cord injury patients. Spinal Cord 43: 199-203
4. Geisler FH et al. (2001) Measurements and recovery patterns in a multicenter study of acute spinal cord injury. Spine 26 (Suppl): S68-S86
5. Fehlings MG and Baptiste DC (2005) Current status of clinical trials for acute spinal cord injury. Injury 36 (Suppl 2): S113-5122
6. Sharma HS et al. (2005) Neuroprotective effects of nitric oxide synthase inhibitors in spinal cord injury-induced pathophysiology and motor functions: An experimental study in the rat. Ann NY Acad Sci 1053: 422-434
7. Beattie MS (2004) Inflammation and apoptosis: Linked therapeutic targets in spinal cord injury. Trends Mol Med 10: 580-583
8. Takami T et al. (2002) Methylprednisolone and interleukin-10 reduce gray matter damage in the contused Fischer rat thoracic spinal cord but do not improve functional outcome. J Neurotrauma 19: 653-666
9. Pearse DD et al. (2004) Transplantation of Schwann cells and olfactory ensheathing glia after spinal cord injury: Does pretreatment with methylprednisolone and interleukin-10 enhance recovery? J Neurotrauma 21: 1223-1239
10. Gorio A et al. (2005) Methylprednisolone neutralizes the beneficial effects of erythropoietin in experimental spinal cord injury. Proc Natl Acad Sci USA 102: 16379-16384
11. Jones TB etal. (2005) Inflammatory-mediated injury and repair in the traumatically injured spinal cord. Curr Pharm Des 11: 1223-1236